NASDAQ · BCTX
Healthcare · Biotechnology
$3.56
Up+$0.43 (+12.08%)
Updated Sep 17, 2026, 6:52 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
BCTX closed at $3.56 after 20 trading sessions, down 10.10% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $3.57 | $3.62 | $3.52 | $3.56 | 66.37K |
| Sep 15, 2026 | $3.57 | $3.58 | $3.48 | $3.58 | 68.79K |
| Sep 14, 2026 | $3.58 | $3.65 | $3.56 | $3.56 | 96.22K |
| Sep 11, 2026 | $3.68 | $3.769 | $3.61 | $3.63 | 74.71K |
| Sep 10, 2026 | $3.58 | $3.65 | $3.58 | $3.60 | 39.41K |
| Sep 9, 2026 | $3.62 | $3.75 | $3.5501 | $3.63 | 126.31K |
| Sep 8, 2026 | $3.57 | $3.62 | $3.42 | $3.575 | 145.17K |
| Sep 4, 2026 | $3.48 | $3.60 | $3.46 | $3.57 | 108.26K |
| Sep 3, 2026 | $3.62 | $3.6305 | $3.49 | $3.53 | 67.75K |
| Sep 2, 2026 | $3.58 | $3.76 | $3.57 | $3.57 | 95.41K |
| Sep 1, 2026 | $3.625 | $3.65 | $3.4986 | $3.63 | 109.45K |
| Aug 31, 2026 | $3.72 | $3.80 | $3.47 | $3.59 | 260.69K |
| Aug 28, 2026 | $3.71 | $3.76 | $3.6046 | $3.73 | 234.94K |
| Aug 27, 2026 | $3.93 | $3.9526 | $3.60 | $3.71 | 395.22K |
| Aug 26, 2026 | $3.65 | $4.08 | $3.6445 | $4.03 | 281.15K |
| Aug 25, 2026 | $3.61 | $4.10 | $3.55 | $3.77 | 671.14K |
| Aug 24, 2026 | $4.045 | $4.05 | $3.45 | $3.46 | 8.72M |
| Aug 21, 2026 | $3.99 | $4.18 | $3.965 | $4.07 | 150.44K |
| Aug 20, 2026 | $3.97 | $4.18 | $3.90 | $3.93 | 255.84K |
| Aug 19, 2026 | $3.56 | $4.015 | $3.56 | $3.96 | 319.88K |
The latest Smart Investors Daily articles mentioning BCTX.
BCTX research
Company profile and research snapshot.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Sep 8, 2026
Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)BriaCell Phase 3 trial featured in Nature Medicine as "Eleven clinical trials that will shape medicine in 2026" PHILADELPHIA and VANCOUVER,
Benzinga · Aug 24, 2026
Cell-based immunotherapy program is designed to harness patients’ own immune systemsBria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without
Yahoo · Aug 5, 2026
FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancerBria-PROS+ is BriaCell’s next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components designed to enhance clinical efficacy Bria-PROS+ program previously awarded $2 million grant from the US National Cancer Institute PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2026 (GLOBE NEWSWIRE)
Benzinga · Aug 5, 2026
FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancerBria-PROS+ is BriaCell’s next generation personalized immunotherapy for
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BCTX.
